Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)

NCT07257380 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Standard neoadjuvant therapy
PROCEDURE: Radical gastrectomy
DRUG: Standard adjuvant therapy
DRUG: ctDNA-MRD-guided adjuvant therapy

Sponsor

Shanghai Zhongshan Hospital